Application of recombinant adenoviral vectors for cancer gene therapy is currently limited due to lack of specificity for tumor cells. For gastric and esophageal adenocarcinoma, we present here that the relative abundant expression of the primary adenovirus receptor, coxsackie / adenovirus receptor ( CAR ), on normal epithelium compared to carcinoma favors the transduction of the epithelium. As such, to achieve specific transduction of cancer cells, targeting approaches are required that ablate the binding of the virus to CAR and redirect the virus to tumor -specific receptors. By immunohistochemistry and reverse transcriptase polymerase chain reaction assays, we demonstrate a marked difference in expression of the human epithelial cell adhesion molecule ( EpCAM ) between normal and ( pre )malignant lesions of the stomach and esophagus. Based on this, we explored the feasibility of using EpCAM to achieve gastric and esophageal adenocarcinoma selective gene transfer. Adenoviral vectors redirected to EpCAM using bispecific antibodies against the adenovirus fiber -knob protein and EpCAM specifically infected gastric and esophageal cancer cell lines. Using primary human cells, an improved ratio of tumor transduction over normal epithelium transduction was accomplished by the EpCAM -targeted vectors. This study thus indicates that EpCAM -targeted adenoviral vectors may be useful for gastric and esophageal cancer ± specific gene therapy in patients. Cancer Gene Therapy ( 2001 ) 8, 342 ± 351
G astric and esophageal cancers are two of the most common causes of cancer-related death in the World. Current treatment strategies include surgery, chemotherapy, and radiotherapy, but these are limited in their therapeutic efficacy. 1 Therefore, it is apparent that novel therapeutic modalities are required for treatment of these diseases. In this regard, gene therapy represents a rational approach for treatment of gastric and esophageal adenocarcinomas. The aim of cancer gene therapy is to improve current treatment modalities based on a better tumor selectivity. To date, adenoviral vectors are widely applied to transfer genes into tumor cells because they can be produced in high titers and can infect many different cell types. However, widespread application of adenoviral vectors for cancer gene therapy is hampered due to lack of specificity for malignant cells because the receptor for the adenovirus (Ad ), coxsackie / adenovirus receptor (CAR ), is expressed on both normal and malignant human cells. Retargeting of adenovirus toward alternative receptors selectively expressed on tumor cells might circumvent this limitation by increasing the specificity and efficacy of gene transfer. 2, 3 A potential target for gene therapeutic vectors is the 40-kDa protein product of the GA733 -2 gene:
4 ± 8 the epithelial cell adhesion molecule ( EpCAM ). EpCAM is a surface antigen defined by several monoclonal antibodies, e.g., 323 / A3. 9 The EpCAM glycoprotein modulates cadherin-mediated intercellular connections, and a role for this molecule in tumor cell growth and invasion has been suggested. 10 ± 12 EpCAM has attracted attention as a tumor marker because EpCAM is overexpressed in the majority of adenocarcinomas compared to their normal epithelial counterparts. 9,13 ± 16 Targeting of adenoviral vectors toward tumor cells via EpCAM can be achieved by utilizing a bispecific immunoconjugate consisting of the Fab H domains of a neutralizing antibody against the adenovirus fiber -knob ( binding domain for CAR ) and an anti -EpCAM antibody. 17 The function of this conjugate is 2-fold: ( a) it blocks the natural binding of adenovirus to CAR present on many different cell types, and ( b) it directs the adenovirus to EpCAM-expressing cells.
In the present study, we sought to determine the utility of adenoviral vectors for gene therapy to human gastric and esophageal cancer, and we explored the feasibility of using EpCAM as target for achieving gastric and esophageal adenocarcinoma± selective gene transfer.
MATERIALS AND METHODS

Cells, viruses, antibodies, and conjugate
The human gastric carcinoma cell line KatoIII (gastric signet ring cell carcinoma ) and the human ovarian cancer cell line OvCAR -3 were obtained from American Type Culture Collection ( Rockville, MD ). CHO cells were kindly provided by the Department of Human Genetics, University Hospital Vrije Universiteit, Amsterdam ( Courtesy of Dr. H. Joenje). The human malignant glioma cell line U373 was kindly provided by the Department of Radiobiology, University Hospital Vrije Universiteit. MKN -28 ( welldifferentiated gastric carcinoma ) and MKN -45 ( poorly differentiated gastric carcinoma ) cells were kindly provided by Dr. M. Tsujii ( Osaka University School of Medicine, Japan ). HM02 (well -differentiated gastric carcinoma ) and HM51 ( undifferentiated gastric carcinoma ) cells were kindly provided by the Department of Medical Microbiology, Academic Medical Center, Amsterdam (courtesy of Dr. A. van der Ende ). 18 The esophageal cancer cell lines TE -1 and TE -2 were kindly provided by Dr. Nishihira (Tohoko University, School of Medicine, Japan ). The cells were cultured at 378C in a 5% CO 2 atmosphere in DMEM ( KatoIII, HM02, HM51, OvCAR -3, CHO, and U373 ) or RPMI 1640 (MKN -28, MKN -45, TE -1, and TE -2 ), supplemented with 10% FCS, penicillin, streptomycin, and L -glutamine.
Primary human gastric or esophageal epithelial and cancer cells were obtained from six patients undergoing tumor resection. Tumor specimens were excised from surrounding normal epithelium and both normal parts and tumor parts were cut into smaller pieces. Single cell suspensions were prepared by repetitive incubation with Liver Digest Medium ( Life Technologies, Breda, the Netherlands ) essentially as described before. 17 AdCMVluc is an E1 /E3 -deleted replication-deficient Ad5 vector, which expresses firefly luciferase under the control of the immediate -early cytomegalovirus (CMV ) promoter that was obtained from R.D. Gerard ( University of Texas Southwestern Medical Center, Dallas, TX ). The viruses were propagated on the permissive cell line 293 and purified by centrifugation on CsCl gradients by standard techniques. 19 All virus aliquots were stored at À 808C until use. All gene transfer studies were performed with a single lot of AdCMVluc ( 3.6Â10 11 part / mL as determined by OD 260 measurement; 3.3Â10 11 pfu /mL as determined by limiting dilution ).
The neutralizing murine monoclonal antibody ( mAb ) 1D6.14 specific for the receptor binding domain of adenovirus serotype 5 has been described previously. 20 The mAb 323/ A3 ( provided by Prof. S. Warnaar, Centocor, Leiden, the Netherlands ) is reactive with the pan -carcinoma antigen EpCAM. 9 Mouse monoclonal antibody RmcB to human CAR ( a generous gift of Dr. Robert Finberg, DanaFarber Cancer Institute, Harvard Medical School, Boston, MA ) has been previously described. 21 Bispecific conjugate of 1D6.14 Fab H and 323 /A3 Fab H was produced by chemical linkage as previously described. 17 
Tissue specimens
Resected primary gastric adenocarcinoma specimens from 30 patients diagnosed in the period 1984 ± 1999 were selected from the files of the Pathology Department (University Hospital Vrije Universiteit ). For each tumor, both formalinfixed and frozen tissues were available ( n= 30). In addition, normal mucosa specimens from different sites of the stomach ( cardia, body, and antrum ) were selected including normal gastric mucosa samples of subjects without cancer (frozen n = 5; formalin-fixed n =3 ) and normal mucosa samples distant from the tumor in patients with gastric adenocarcinoma (frozen n = 6; formalin-fixed n =20 ). Selection of all samples was based on the following criteria: (a ) an optimal preservation of morphology of tissue sections, (b ) the capability to obtain sufficient RNA of proper quality for reverse transcriptase polymerase chain reaction ( RT-PCR ), ( c) an area of more than 50% consisting of tumor and absence of normal epithelium in the frozen tumor sections, and (d ) more than 50% of epithelial cells in the frozen sections of normal epithelium.
For formalin -fixed paraffin-embedded tissue specimens, consecutive 4-m sections were cut and used for immunohistochemistry ( IHC ) and haematoxylin ±eosin ( H&E ) staining. Using the H&E -stained sections, the tumor histology according to Lauren 22 and the grade of differentiation of the tumors according to the criteria of the World Health Organization 23 were reassessed. Tumors were staged according to TNM classification. 24 For frozen specimens, consecutive 4-m sections were cut, the first and last of which were stained with H&E for careful histomorphological examination. This examination also included a crude estimation of the percentage of neoplastic or histomorphologically normal epithelial cells relative to surrounding stromal cells, as needed for selection of the samples. Series of in -between sections of the frozen specimens was used for IHC or for extracting RNA for RT-PCR purposes.
Immunohistochemistry
For CAR IHC, 4-m frozen sections were cut and fixed in acetone /H 2 O 2 and endogenous biotin was blocked using savidin and d-biotin. Subsequently, sections were incubated with normal rabbit serum followed by mAb RmcB. Bound primary antibody was detected with a biotinylated secondary antibody and streptavidin ±peroxidase complex using diaminobenzidine tetrahydrochloride as the substrate. Finally, sections were counterstained with haematoxylin, dehydrated, and mounted.
EpCAM IHC was performed using 4 -m sections of the paraffin -embedded formalin -fixed specimens. The sections were dewaxed in xylene, rehydrated in graded ethanols according to standard procedures, and endogenous peroxidase was blocked using 0.3% H 2 O 2 in methanol. Antigen retrieval was performed using 0.1% pepsin in 0.02 N HCl before applying mAb 323 /A3. Bound primary antibody was detected as described above.
Negative controls included parallel sections that were treated without the primary antibody or with an irrelevant primary antibody of the same ideotype. For CAR IHC, liver tissue was used as positive control. One primary tumor that consistently stained for EpCAM was used as positive control for EpCAM in each series of sample processing and immunodetection. At least two different paraffin-embedded parts of the same specimen were stained to reveal heterogeneity in staining pattern. All sections were stained in duplicate. Immunoreactivity was preferentially localized on the cell membrane with some minor staining in the cytoplasm. The classification of the immunoreactivity in the samples was performed by a pathologist ( EB ) blinded to the results of the RT-PCR. Positivity was scored by using a product score system consisting of a cellular proportion score and an intensity score. The product score was calculated as (% positive cellsÂstaining intensity ). The intensity of immunostaining was graded as 0= negative, 1 =weakly positive, 2 =positive, and 3= strongly positive. The percentage of cells was classified as 1 = 0± 25%, 2 =26 ± 50%, 3= 51 ±75%, 4 = >75%.
Detection of EpCAM mRNA by RT -PCR
The oligonucleotides used for EpCAM RT-PCR assays are summarized in Table 1 . Primers FPepcam and RPepcam direct the amplification of a 220 -bp cDNA fragment in the PCR.
First, total RNA was extracted from cryosections of the series of frozen gastric primary adenocarcinoma specimens ( n= 30) and normal gastric mucosa samples of subjects with ( n= 6) or without (n =5 ) gastric adenocarcinoma, as well as of cell pellets of the cell lines KatoIII, HM02, and HM51. RNA extraction was performed using RNAzol B, according to the instructions of the manufacturer ( Campro Scientific, Veenendaal, The Netherlands ).
Fifty to five hundred nanograms of total RNA was used to synthesize first strand cDNA as described 25 using the antisense primer for the housekeeping gene small nuclear ribonucleoprotein specific A protein U1A (snRNP U1A ) ( primer U1A2 ) 25 and the antisense primer specific for EpCAM ( primer RPepcam ) in a single reaction. One tenth of the resulting cDNA was used as target for subsequent PCR for EpCAM or snRNP U1A in separate reactions. snRNP U1A analysis served as control for RNA quality. 25 All samples in our study were positive in the snRNP U1A RT-PCR, indicating good RNA quality. Cycle conditions were as follows: 1 minute of denaturation at 948C, 90 seconds of annealing at 608C, and 2 minutes of extension at 728C. For both snRNP U1A and EpCAM PCR assays, 40 cycles were run on a Peltier Thermal Cycler 225 PCR system (MJ Research, Waltham, MA ). To confirm the specificity of the products, PCR products were analyzed by radioactive Southern blot hybridization with oligoprobes PROepcam and U1A3 for EpCAM and snRNP U1A, respectively. The EpCAM transcript was detectable in down to 10 pg of HM02 RNA after 40 cycles, as determined by analyzing a serial dilution of RNA of this gastric carcinoma cell line. Assuming that one cell contains approximately 10 pg of RNA, this indicates that the EpCAM RT-PCR allows the detection of EpCAM mRNA in a single HM02 cell.
For each sample in this study, the detection of EpCAM mRNA expression was done in duplicate. In each series of sample processing and detection, samples containing Oligonucleotides used in this study were selected using the PCRPLAN program of the PC / Gene software ( IntelliGenetics, Campbell, CA ). Primers were selected on the sequence of the GA733 -2 gene 7 for amplification of EpCAM mRNA. All oligonucleotides were selected in such a way to flank putative splice junctions, allowing a discrimination between amplification of spliced cDNA and co -amplification of traces genomic DNA possibly present in the RNA sample. See Materials and Methods for the conditions of the RT -PCR assays. nt = nucleotide; FP = forward primer; RP = reverse primer; PRO = internal oligonucleotide probe. distilled water and samples without reverse transcriptase enzyme were included as negative controls, and HM02 cells were included as positive control. Samples were classified according to their relative EpCAM expression level (namely, intensity of EpCAM relative to intensity of snRNP U1A ) normalized to a reference. Samples were scored as negative ( no EpCAM), weakly positive ( moderate EpCAM expression ), or positive ( high EpCAM expression ). Scoring was performed by persons ( M. C., P. S.) blinded to the results of IHC.
Phenotypic analysis of cell lines and primary human cells
Analysis of the level of EpCAM expression on cell lines and single cells suspensions was performed by FACS analysis. Cells were stained using the mAb 323/ A3 at 10 g/mL in PBS for 1 hour at 08C. After washing and incubation with a FITC -conjugated rabbit±antimouse IgG antibody (Dako, Glostrup, Denmark ), the samples were fixed in 1% formaldehyde in PBS, and analyzed on a FACScan using CellQuest analysis software ( Becton Dickinson, Franklin Lakes, NJ, USA ). EpCAM expression levels on the cell lines were classified relative to the expression level on OvCAR -3 cells, known to express high levels of EpCAM. CHO cells were used as negative control.
In addition, the level of CAR expression on the cell lines was determined by FACS analysis, exactly as described above, using mAb RmcB at 10 g /mL. CAR expression levels on the cell lines were classified relative to the expression level on U373 cells, known to express high levels of CAR. CHO cells were used as negative control.
Adenoviral vector infection and analysis of gene transfer
Adenovirus was targeted to EpCAM through a bispecific antibody conjugate (anti -EpCAM/ antiknob ). The optimal ratio of immunoconjugate to AdCMVluc for targeted gene transfer into EpCAM -positive cells and for decreased gene transfer into EpCAM -negative cells was determined by titration. Conjugate and virus were mixed and incubated for 30 minutes at room temperature in a minimal volume. The complexes were added in triplicate to OvCAR -3 or U373 cells, plated 24 hours earlier in 24-well plates at a density of 10 5 cells / well. Following incubation for 30 minutes at room temperature, the virus -containing medium was replaced by 1 mL culture medium and cells were grown for 22 hours at 378C. The cells were then lysed and extracts were assayed for luciferase activity via a luciferase assay system ( Promega, Madison, WI ) using a luminometer (Lumat LB9507, EG&G Berthold, Bad Wildbad, Germany ). Results Gene transfer studies to compare EpCAM -targeted and native AdCMVluc were performed using the gastric cancer cell lines HM02, HM51, KatoIII, MKN -28, MKN -45, and the esophageal cancer cell lines TE -1 and TE -2. OvCAR -3 cells displaying high levels of EpCAM and CAR were used as positive control and CHO cells, negative for both EpCAM and CAR, as negative control. Experiments were performed essentially as described above, except for KatoIII. These semifloating cells were cultured in tubes (10 5 cells / tube ) and centrifuged before reagents change. Three independent targeting experiments, each performed in triplicate, were done for each cell line.
Binding specificity of the EpCAM -targeted or native AdCMVluc was evaluated by inhibition studies where target cells were preincubated with excess unconjugated 323 /A3 mAb or recombinant adenovirus fiber-knob at 100 g/ml in PBS for 30 minutes. Anti -EpCAM antibody 323 /A3 was used to bind to EpCAM molecules at the cell surface, and recombinant fiber-knob to block CAR -binding at the cell surface. Subsequently, an infection was performed with EpCAM -targeted or native AdCMVluc as above. Three independent experiments, each performed in triplicate, were done for each cell line.
EpCAM -targeted and native AdCMVluc were compared on primary cells freshly isolated from patient material. OvCAR -3 and U373 cells were used as controls. Experiments were performed essentially as described above for KatoIII cells. Binding specificity of the EpCAM-targeted or native AdCMVluc was evaluated by inhibition studies where target cells were preincubated with excess unconjugated 323 /A3 mAb or recombinant fiber-knob as above. Results were expressed as RLU per microgram protein. The amount of protein in each sample was measured by Bio -Rad protein assay according to the instructions of the manufacturer ( BioRad Laboratories, Richmond, CA ).
Statistics
Statistical analysis of data was performed using Fischer's exact test, Student's t test, Spearman correlation test, or Mann ± Whitney test. For each single analysis, the statistical test used is stated in the text. Differences were considered significant when P < .05.
RESULTS
Transduction of primary cells using a recombinant adenoviral vector
To be clinically effective, gene therapy interventions require transduction of target cells with adequate efficiency to realize the potential therapeutic benefit of the delivered transgenes. Therefore, we determined the utility of adenoviral vectors for transduction of primary gastric and esophageal tumor cells. Primary cells freshly isolated from resected tumor pieces or non -neoplastic epithelial counterparts were transfected using AdCMVluc. In five of six clinical specimens, the adenoviral vectors infected the normal epithelial cells more efficiently than the tumor cells (Fig 1 ) .
To determine the biological basis for this relative resistance of tumor tissue for adenoviral infection, we investigated the expression of the primary adenovirus receptor CAR in normal and malignant gastric and esophageal tissue. In our series of adenocarcinoma samples, CAR immunoreactivity was observed across all types of adenocarcinomas, but staining intensities ranged from negative up to highly positive between different areas of the tumor (median product score of 8, range 1± 12 ) (Fig 2A   Figure 4 . Expression of EpCAM: RT -PCR. Total RNA was extracted from a series of patients' resection material as well as cell lines, and used to synthesize first strand cDNA. The resulting cDNA was subjected to PCR for EpCAM and snRNP U1A. snRNP U1A analysis served as control for RNA quality. Specificity of the products was checked by Southern blot hybridization. The results of snRNP U1A ( upper set ) and EpCAM ( lower set ) RT -PCR assays after 40 cycles of amplification are given for a representative panel of RNA samples. Samples on gel from left to right: ( 1 ) Marker, ( 2 ) Negative Control, ( 3 ) KatoIII, ( 4 ) HM02, ( 5 ) HM51, ( 6 ± 9 ) four normal gastric mucosa samples, and ( 10 ± 13 ) four gastric adenocarcinoma samples. *EpCAM expression ( ratio of mean fluorescence intensity of sample over mean fluorescence of second antibody control ) was determined by FACS analysis using mAb 323 / A3. When available, results of two independent FACS analyses are indicated as mean SD.
yCAR expression ( ratio of mean fluorescence intensity of sample over mean fluorescence of second antibody control ) was determined by FACS analysis using mAb RmcB. When available, results of two independent FACS analyses are indicated as mean SD.
zThe cell lines in this table are arranged according to an increasing ratio of mean EpCAM expression over mean CAR expression. HEIDEMAN, SNIJDERS, CRAANEN, ET AL: GASTRIC AND ESOPHAGEAL CANCER-SPECIFIC GENE TRANSFER and C ). Non -neoplastic adjacent gastric epithelium in the tumor specimens, the gastric mucosa from subjects without cancer, and normal squamous esophageal epithelium present in some sections all highly expressed CAR (median product score of 12, range 8 ±12 ) (Fig 2B and D ) . No CAR immunoreactivity was seen on stromal cells, lymphoid cells, or endothelial cells. Overall, quantitative estimation of CAR expression using the product score indicated that the expression of CAR in the normal epithelia samples was significantly higher than the expression of CAR in the tumors (Mann -Whitney test: P < .01 ).
Thus, the relative abundant expression of CAR in normal epithelium compared to tumor tissue may explain the prominent transduction of normal epithelial cells. Therefore, targeting approaches, which ablate the binding of the virus to CAR and redirect the virus to tumor-specific receptors to achieve specific transduction of gastric or esophageal cancer cells, are required.
EpCAM expression in normal and ( pre )malignant gastric and esophageal tissue
To achieve selective transduction of gastric and esophageal cancer cells, we investigated the expression of a potential target for adenoviral vectors, the human EpCAM, in these tissues. No EpCAM protein expression was observed in normal gastric epithelium (Fig 3A ) and normal squamous esophageal epithelium, except for some staining in the mucus -secreting esophageal glands. Normal duodenal epithelium did express EpCAM. Interestingly, intestinal metaplasia found in 9 of 20 normal gastric mucosa specimens of patients with gastric cancer had intensive membrane staining (Fig 3B ) . This expression pattern could perhaps be expected from the EpCAM expression in the duodenum because intestinal metaplasia represents gastric mucosa that has undergone metaplastic transformation into a form of epithelium similar to that seen in the small intestines. In the series of gastric adenocarcinoma samples, 2 /30 tumors showed no or hardly any EpCAM protein expression, 25/30 tumors homogeneously expressed EpCAM in more than 80% of their tumor cells (Fig  3C ± D ) , and in 3 /30 specimens, EpCAM -positive as well as EpCAM -negative tumor cell populations were found. For some tumors also, tumor-containing lymph nodes were present in the sections, and the metastatic tumor cells did express EpCAM when the primary tumor also expressed the antigen ( not shown ).
Overall, quantitative estimation of EpCAM expression using the product score indicated that the expression of EpCAM in the tumor samples ( median product score of 10, range 0± 12) was significantly higher than the expression of EpCAM in the normal gastric and esophageal epithelia ( median product score of 0, range 0± 1 ) (Mann -Whitney test: P < .01). Correlation of the EpCAM expression status of the adenocarcinoma samples to the clinicopathological features of the tumors revealed no significant association between EpCAM expression and Lauren type, histological grade, tumor localization, tumor stage, or lymph node metastasis (Fisher's exact test, data not shown ). To verify the immunohistochemically observed absence of EpCAM expression in normal gastric epithelium, additional EpCAM RT-PCR assays were performed (Fig 4 ) . All normal gastric mucosa specimens were negative ( n =7) or very weak ( n= 4 ) for EpCAM mRNA, whereas all tumors expressed EpCAM mRNA ( five samples weakly positive and 25 samples positive ). The gastric adenocarcinoma cell lines KatoIII, HM02, and HM51 were all positive for EpCAM mRNA.
EpCAM -targeted transduction of gastric and esophageal cancer cell lines with a recombinant adenoviral vector
To investigate whether the high expression of EpCAM in the carcinoma cells allows specific gene transfer toward these cells, adenovirus targeting studies were performed ( Table 2 ) . The EpCAM and CAR expression of the cell lines to be used for these studies was first determined by FACS analysis. All gastric and esophageal carcinoma cell lines showed generally high, but variable, levels of EpCAM expression. Moreover, all carcinoma cell lines expressed CAR, although not all, as high as the positive control.
Adenovirus was targeted to EpCAM through a bispecific antibody conjugate ( anti -EpCAM/antiknob ). EpCAMtargeted AdCMVluc demonstrated up to 12 times enhanced gene transfer to gastric and esophageal cancer cells relative to native AdCMVluc ( Table 2 ). The [EpCAM -targeted/ native transduction] ratio directly correlated with the [ EpCAM / CAR expression ] ratio of the cells ( Spearman correlation: r 2 = .42, P <.05 ). Furthermore, when the EpCAM antigen on the cells was blocked by 323 /A3 antibody, infection by native adenovirus was not affected, whereas up to 95% reduction in EpCAM-targeted gene transfer was observed (Fig 5 ) . These observations indicated the EpCAM specificity of the targeted virus. Conversely, when the cells were preincubated with excess recombinant fiber-knob to block CAR, gene transfer of native AdCMVluc was reduced ( about 80% ), whereas targeted gene transfer was unaffected. This demonstrated that EpCAM -targeted adenoviral infection is independent of the natural adenovirus receptor CAR on the cell surface.
EpCAM -targeted transduction of primary human cells with a recombinant adenoviral vector
Finally, the utility of the EpCAM -targeting approach for achieving selective transduction of the cancer cells was confirmed on human primary gastric or esophageal epithelial and tumor cells. Table 3 shows the results of six clinical samples: the viral infections of normal and tumor cells of the same patient were compared. Five of six tumors expressed EpCAM as determined by IHC on tissue sections, and expression of the antigen after isolation of cells from the clinical specimens was reconfirmed by FACS analysis. In all samples, EpCAM targeting resulted in decreased gene transfer to normal epithelial cells (up to 90% ), whereas gene transfer to the tumor was less affected except for the single tumor that lacked the expression of EpCAM. Thus, in contrast to native AdCMVluc, EpCAM -targeted AdCMVluc generally exhibited a positive ratio of tumor over normal tissue transduction. Some decrease in the absolute gene transfer to the tumor by EpCAM-targeted adenovirus compared to native adenovirus was observed. This can be explained by heterogeneous EpCAM expression in the tumor single cells suspensions. Figure 6 shows that the single cell suspension comprises two cell populations, an EpCAMexpressing and an EpCAM -negative population. As observed for the cell lines, the EpCAM-targeted adenoviral infection of primary cells was also independent of CAR, and EpCAM-specific (data not shown). Thus, EpCAM -targeted adenoviral vectors may be used to direct gene transfer specifically to EpCAM -expressing tumor cells sparing normal tissues.
DISCUSSION
The clinical application of adenoviral vectors that show gastric and esophageal cancer ±specific gene transfer might enhance the therapeutic index of current treatment modalities by, on one hand, increasing the effect of the treatment on tumor cells and, on the other hand, decreasing the toxicity to functionally normal cells. In the case of gastric and esophageal cancer, a first line of targeting can be achieved by luminal access to the tumor via endoscopy and direct injection of vectors into the tumor. However, epithelial cells neighboring the tumor cells will still be transduced via this approach because epithelial cells have high CAR expression. Thus, targeting strategies are required to obtain direct gene transfer specifically to tumor cells and to spare normal tissues. To accomplish such selective gene transfer, a cell surface molecule, which is selectively expressed on tumor cells and allows the adenoviral vector to enter the target cell and to transfer its therapeutic gene, is needed. In this study, the human surface antigen EpCAM was found to be such a target, being predominantly expressed on ( pre )malignant lesions of the stomach and esophagus and allowing specific gene transfer to gastric and esophageal cancer cells in vitro. In agreement with the study of Songun et al, 26 we observed no significant association between EpCAM expression and clinicopathological features of the tumors. Most likely, this is due to the high prevalence of high EpCAM expression in the gastric adenocarcinomas. The differential expression of EpCAM in normal versus neoplastic gastric and esophageal tissue observed in this study is in accordance with other studies, 11, 16, 27 except for one study reporting strongly positive stained normal gastric epithelium. 15 Because various immunohistochemical studies are difficult to compare due to, e.g., different antibodies used, additional RT-PCR was performed here. Our RT-PCR data are in accordance with the immunohistochemically observed absence of EpCAM in the majority of normal gastric epithelia. The few normal samples that expressed very weak PCR bands can be explained by the relatively high sensitivity of the EpCAM RT-PCR assay. Thus, apparently overexpression of EpCAM in (pre )neoplastic gastric and esophageal tissue is due to a deregulated control at the transcriptional level. High EpCAM expression in intestinal metaplasia reported herein was observed previously. 11, 27 Because gastric carcinogenesis is presumed to be a sequential process leading from normal gastric mucosa via various precursor stages, including intestinal metaplasia, to carcinoma, 28 an increase in EpCAM expression might be seen as an early pathogenic event in gastric carcinogenesis, which favors the malignant transformation of epithelial cells.
Currently, many cellular receptors such as epidermal growth factor receptor, 29, 30 folate receptor, 20 and fibroblast growth factor receptor, 31 are under investigation for their feasibility of redirecting adenovirus to cancer cells using complexes of adenovirus particles with bispecific conjugates that simultaneously ablate endogenous viral tropism and introduce novel tropism by a ligand or an antibody against the novel target. Here we show that EpCAM is an important target for gastric and esophageal cancer gene therapy. First, the marker is hardly detectable on normal gastric and esophageal epithelium, making it possible to really target the adenoviral vectors to the gastric and esophageal tumor cells. The expression of EpCAM in the small intestines will most likely give no difficulties to safe treatment because local intratumoral injection of the vectors by endoscopy will limit leakage of the vector to the duodenum, and to increase safety, the flow from the stomach to the duodenum can be partitioned off during the injection period. Second, the high incidence of EpCAM expression in gastric carcinomas makes EpCAM targeting a widely applicable approach. Although EpCAM is heterogeneously expressed in some tumors, this will most likely not limit the usefulness of EpCAM targeting because the strategy can be combined with vectors containing a payload that induces a``bystander effect'' on tumor cells that will not be transduced by the vector themselves. Third, because adenovirus has been shown to be transferred into regional lymph nodes of the stomach after direct injection into the tumor located in the stomach, 32 the expression of EpCAM on metastatic tumor cells in the lymph nodes renders EpCAM-specific gene therapy interesting for treatment of metastatic foci as well. Fourth, EpCAM targeting of adenovirus has been previously shown to dramatically reduce gene transfer into human liver cells. 17 Therefore, potential leakage of the EpCAM -targeted adenovirus into the bloodstream is not expected to result in systemic toxicity such as hepatotoxicity. Finally, EpCAM might have an advantage over alternative targets on gastric and esophageal cancer cells because the molecule is also expressed on precancerous lesions, such as intestinal metaplasia. Because these precancerous lesions are often present in the stomach at sites adjacent to the tumor, the EpCAM-targeted virus might be able to diffuse to the precancerous cells after direct injection into the tumor, thereby allowing transfer of therapeutic genes into these EpCAM-expressing precursor cells. As a consequence, the efficacy of this EpCAM -targeted gene therapy is most likely increased compared to therapies only affecting tumor cells by additional elimination of cells that have a high chance of becoming malignant.
CONCLUSION
The marked difference in EpCAM expression between normal and (pre )malignant lesions of the stomach and esophagus as well as the specific EpCAM -targeted gene transfer toward ( primary ) gastric and esophageal cancer cells indicate that this receptor is a good candidate for targeting adenoviral vectors to gastric and esophageal cancer in patients. EpCAM targeting, in combination with vectors containing a powerful payload, may provide a selective and effective treatment for gastric and esophageal cancer.
